SCHEMBL4868697

SCHEMBL4868697

CCN(C(=O)[C@H](C)NC(=O)N1CCCOc2cc(F)ccc21)c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.40
MET P08581 3/20 0.35
LCK P06239 2/20 0.35
KDR P35968 2/20 0.35
AGTR2 P50052 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
IDO1 P14902 2/20 0.34
KCNH2 Q12809 2/20 0.34
LMNA P02545 1/20 0.34
TEK Q02763 1/20 0.34
DGAT1 O75907 1/20 0.34
SOAT2 O75908 1/20 0.34
SOAT1 P35610 1/20 0.34
MAPT P10636 1/20 0.33
ATM Q13315 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
THRB P10828 1/20 0.32
CTSL P07711 1/20 0.32
CTSS P25774 1/20 0.32
CTSK P43235 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4863306 0.91 THRB (0.42) LMNAMAPTTHRBPOLBMEN1
SCHEMBL4867148 0.77 POLB (0.48) LMNAMAPTATMTHRBPOLB
SCHEMBL4867654 0.77 POLB (0.48) LMNAMAPTATMTHRBPOLB
SCHEMBL4860776 0.76 LMNA (0.43) KCNQ2METLCKKDRTDP1
SCHEMBL4871095 0.74 MAPT (0.43) LMNAMAPTL3MBTL1THRBPOLB
SCHEMBL6677980 0.74 MEN1 (0.45) LMNAMAPTTHRBPOLBMEN1
SCHEMBL4866045 0.73 KMT2A (0.50) KCNQ2METLCKKDRTDP1
SCHEMBL4869531 0.71 KMT2A (0.47) LMNADGAT1MAPTL3MBTL1MEN1
SCHEMBL25937553 0.71 KCNQ2 (0.45) KCNQ2AGTR2DGAT1SOAT2SOAT1
SCHEMBL4869590 0.69 KCNQ2 (0.45) KCNQ2KDRAGTR2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368444-B2 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 US disclosed
EP-1475368-A1 N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101600-A1 N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient CNR1, CNR2, NPSR1 KCNQ2 773/4885MET 887/4885LCK 4737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.